Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCS110 in prostate cancer with bone metastases
NCT00757757Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2008
- Primary completion
- Aug 2009
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lacnotuzumab in prostate cancer (PCa), sponsored by Novartis. Started Sep 2008; status: terminated.
02
Drugs
lacnotuzumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00757757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00757757.